All Updates

All Updates

icon
Filter
Partnerships
Oncodesign Precision Medicine and Navigo Proteins partner for systemic radiotheranostic agents development
Precision Medicine
May 15, 2024
This week:
Product updates
Burcon unveils canola protein isolate for egg replacement
Plant-based Dairy & Egg
Yesterday
Product updates
Bene Meat Technologies produces first cultivated burger at parity with premium beef
Cell-cultured Meat
Yesterday
Geographic expansion
Regulation/policy
The Better Meat Co. expands to Asia with Singapore approval for Rhiza mycoprotein
Plant-based Meat
Yesterday
Listing
Pony.ai files for US IPO
Auto Tech
Yesterday
Product updates
MineOS launches DSR management 2.0
Digital Privacy Tools
Yesterday
Product updates
LatticeFlow launches the first evaluation framework for EU AI Act compliance
Generative AI Infrastructure
Yesterday
Product updates
Cognitive3D launches custom dashboards for XR analytics
Extended Reality
Oct 16, 2024
Funding
Mindtech raises GBP 4.4 million in funding to develop AI vision technology
Extended Reality
Oct 16, 2024
Partnerships
Zscaler and Okta partner to enhance zero trust security initiatives
Identity & Access Management
Oct 16, 2024
Partnerships
Zscaler and Okta partner to enhance zero trust security initiatives
Next-gen Cybersecurity
Oct 16, 2024
Precision Medicine

Precision Medicine

May 15, 2024

Oncodesign Precision Medicine and Navigo Proteins partner for systemic radiotheranostic agents development

Partnerships

  • Navigo Proteins and Oncodesign Precision Medicine have entered a partnership focusing on the advancement of novel systemic radiotheranostic agents used in cancer treatment.

  • The partnership will leverage OPM's technologies and Navigo's proprietary Affilin platform to develop new treatments for resistant and metastatic cancers. The aim is to create radiotheranostic agents that can detect and destroy tumor cells, a method that's been clinically successful in treating specific types of cancers. The partnership will initially focus on two targets in oncology and develop molecules to the stage of drug candidates. The companies also aim to expand the partnership to additional targets. 

  • Headquartered in Germany, Navigo Proteins is a biotechnology company specializing in protein engineering. Its focus is on developing precision affinity ligands and biotherapeutics. Navigo Proteins uses its proprietary platforms, Precision Capturing and Precision Targeting, to create custom affinity chromatography solutions and novel biotherapeutics, respectively.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.